Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors.

Competing Interests: Conflicts of interest Outside the submitted work, Dr Nicole R. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Fortress Biotech, Silverback and Synox Therapeutics. Mr Daniel Y. Kim is a scientific consultant at Verve Therapeutics and SeQure Dx. His conflicts of interests are managed by the Mass General Brigham in accordance with their conflict-of-interest policies. The other authors do not have conflicts of interest to disclose.